The DOI matches its Crossref record.
Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism
Abstract
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a fundamental process during cancer progression. Anti-angiogenic strategies have been pursued for cancer treatment and prevention of cancer recurrence and metastasis. Integrins are a family of cell adhesion molecules consisting of two non-covalently bound transmembrane subunits (α3 and β). Much research has demonstrated that integrin signaling plays a key role in tumor angiogenesis and metastasis. Integrin αvβ3 is highly expressed on activated endothelial cells and tumor cells but is not present in resting endothelial cells and most normal organ systems, which makes it a suitable target for anti-angiogenic cancer therapy. In this review we will focus on cancer therapy targeting integrin αvβ3 while other integrins (such as α5β1, αIIbβ3, αvβ5, α6β4) will only be briefly mentioned when relevant. MEDI-522 (a humanized anti-human integrin avb3 monoclonal antibody) and Cilengitide (cyclic peptidic integrin αvβ3 /αvβ5 antagonist) are currently in clinical trials for anti-angiogenic cancer therapy. Small interfering RNA (siRNA) that specifically silences integrin αv and/or β3 was reported to cause tumor shrinkage in preclinical xenograft models. Combination of anti-integrin αvβ3 therapy and other therapeutic approaches (such as chemotherapy, radiotherapy and gene therapy) has also been applied for cancer treatment. Mounting evidence suggests that there is potentially synergistic effect of combined therapeutic approaches over single modality alone. Lastly, integrin targeted delivery (drugs, genes, and radioisotopes) and imaging (optical, MRI, ultrasound, SPECT, and PET) is discussed in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biomedical Applications of Zinc Oxide Nanomaterials
Zhang, Y., Nayak, T., Hong, H., & Cai, W. (2013) · Current Molecular Medicine · doi:10.2174/1566524013666131111130058 · Cited by 651
Self-citationNanoplatforms for Targeted Molecular Imaging in Living Subjects
Cai, W., & Chen, X. (2007) · Small · doi:10.1002/smll.200700351 · Cited by 563
Self-citationA review on ZnO nanostructured materials: energy, environmental and biological applications
Theerthagiri, J., Salla, S., Senthil, R. A., Nithyadharseni, P., Madankumar, A., Arunachalam, P., Maiyalagan, T., & Kim, H.-S. (2019) · Nanotechnology · doi:10.1088/1361-6528/ab268a · Cited by 530
Modification of kidney barrier function by the urokinase receptor
Wei, C., Möller, C. C., Altintas, M. M., Li, J., Schwarz, K., Zacchigna, S., Xie, L., Henger, A., Schmid, H., Rastaldi, M. P., et al. (2008) · Nature Medicine · doi:10.1038/nm1696 · Cited by 523
Multimodality Molecular Imaging of Tumor Angiogenesis
Cai, W., & Chen, X. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045922 · Cited by 494
Self-citation
Metadata
- Authors
- Cai, W., & Chen, X.
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-09-01
- Volume
- 6
- Issue
- 5
- Pages
- 407-428
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W1963810538
- Cited by
- 235
- References
- 0
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism. https://app.cochat.ai/papers/10.2174/187152006778226530
- The paper
- Cai, W., & Chen, X. (2006). Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism. Anti-Cancer Agents in Medicinal Chemistry. https://doi.org/10.2174/187152006778226530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.